717 – Nirmatrelvir/Ritonavir for Chronic COVID-19: Outcome in 16 Severely Immunocompromised Patients
Background Nirmatrelvir/ritonavir (N/r) is approved for the outpatient treatment of COVID-19 within 5 days of symptom onset and is typically used in patients at increased risk for severe disease. In severely immunocompromised patients, COVID-19 occasionally evolves into a chronic infection. The potential value of N/r in this context including optimal treatment duration is unknown. We…